Increased incidence of seronegative autoimmune hepatitis in children during SARS-CoV-2 pandemia period
| dc.contributor.author | Muriel Schmutz | |
| dc.contributor.author | Suzanne Chartier | |
| dc.contributor.author | Thierry Leblanc | |
| dc.contributor.author | Charlotte Mussini | |
| dc.contributor.author | Antoine Gardin | |
| dc.contributor.author | Emmanuel Gonzales | |
| dc.contributor.author | Anne-Marie Roque-Afonso | |
| dc.contributor.author | Solene Le Cam | |
| dc.contributor.author | Geraldine Hery | |
| dc.contributor.author | Benedicte Neven | |
| dc.contributor.author | Ramy Charbel | |
| dc.contributor.author | Jean-Pierre Vartanian | |
| dc.contributor.author | Emmanuel Jacquemin | |
| dc.contributor.author | Guillaume Morelle | |
| dc.contributor.author | Marion Almes | |
| dc.control.author | Antoine Gardin | |
| dc.control.author | Antoine Gardin | |
| dc.control.author | Emmanuel Gonzales | |
| dc.control.author | Emmanuel Gonzales | |
| dc.control.author | Anne-Marie Roque-Afonso | |
| dc.control.author | Benedicte Neven | |
| dc.control.author | Emmanuel Jacquemin | |
| dc.control.author | Emmanuel Jacquemin | |
| dc.control.author | Guillaume Morelle | |
| dc.control.author | Marion Almes | |
| dc.control.author | Marion Almes | |
| dc.date.accessioned | 2025-06-14T11:33:36Z | |
| dc.date.available | 2025-06-14T11:33:36Z | |
| dc.date.issued | 2024-09-11 | |
| dc.description.abstract | <jats:sec><jats:title>Background</jats:title><jats:p>Seronegative autoimmune hepatitis in children is a rare but potentially severe disease, sometimes requiring liver transplantation. This type of hepatitis may be associated with various immunological and hematological disorders, ranging from isolated lymphopenia to aplastic anemia. Precise pathophysiological mechanisms are still unknown, but the role of viruses cannot be excluded, either as directly pathogenic or as triggers, responsible for an inappropriate immune stimulation. Having the impression of an increasing number of seronegative autoimmune hepatitis since the beginning of SARS-CoV-2 pandemia period, we hypothesized that SARS-CoV-2 virus could be an infectious trigger.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>We conducted a retrospective, observational, descriptive study about children with seronegative autoimmune hepatitis, in a tertiary care center, between 2010 and 2022.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Thirty-two patients were included. The overall incidence of seronegative autoimmune hepatitis increased 3.3-fold in 2020-2022, during the SARS-CoV-2 pandemia period (16 patients in 2.8 years) compared with 2010-2019 the pre pandemia period (16 patients in 9 years). Patients’ clinical and biochemical liver characteristics did not differ between the two periods. Hematological damages were less severe during the pandemia period. Immunological studies revealed a dysregulated immune response. The initiation of immunosuppressive therapy (corticosteroids ± cyclosporine) was earlier during the pandemia period than before.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>In cases of undetermined acute hepatitis, an immune-mediated origin should be considered, prompting a liver biopsy. If the histological aspect points to an immune origin, immunosuppressive treatment should be instituted even though autoimmune hepatitis antibodies are negative. Close hematological monitoring must be performed in all cases. The 3.3-fold increase of cases during the SARS-CoV-2 pandemia will need to be further analyzed to better understand the underlying immunological mechanisms, and to prove its potential involvement.</jats:p></jats:sec> | |
| dc.description.volume | 15 | |
| dc.identifier.doi | 10.3389/fimmu.2024.1445610 | |
| dc.identifier.issn | 1664-3224 | |
| dc.identifier.openaire | doi_dedup___ | |
| dc.identifier.pmc | PMC11425678 | |
| dc.identifier.pmid | 39328418 | |
| dc.identifier.uri | https://ror.circle-u.eu/handle/123456789/510911 | |
| dc.openaire.affiliation | Université Paris Cité | |
| dc.openaire.collaboration | 1 | |
| dc.publisher | Frontiers Media SA | |
| dc.rights | OPEN | |
| dc.rights.license | CC BY | |
| dc.source | Frontiers in Immunology | |
| dc.subject | Male | |
| dc.subject | acute liver failure AST | |
| dc.subject | bone marrow aspiration/biopsy | |
| dc.subject | ALT | |
| dc.subject | polymerase chain reaction | |
| dc.subject | [SDV]Life Sciences [q-bio] | |
| dc.subject | PT | |
| dc.subject | PR | |
| dc.subject | aspartate aminotransferase | |
| dc.subject | LT | |
| dc.subject | BMA/B | |
| dc.subject | Severe Acute Respiratory Syndrome Coronavirus 2 SAIH | |
| dc.subject | magnetic resonance imaging | |
| dc.subject | alanine aminotransferase ALF | |
| dc.subject | Epstein-Barr virus FV | |
| dc.subject | hematopoietic stem cell transplantation Ig | |
| dc.subject | Child | |
| dc.subject | gamma-glutamyl transpeptidase | |
| dc.subject | liver transplantation | |
| dc.subject | Incidence | |
| dc.subject | magnetic resonance imaging PCR | |
| dc.subject | CMV | |
| dc.subject | immunosuppressive treatment | |
| dc.subject | Severe Acute Respiratory Syndrome Coronavirus 2 | |
| dc.subject | coagulation factor V GGT | |
| dc.subject | coagulation factor V | |
| dc.subject | Hepatitis, Autoimmune | |
| dc.subject | PCR | |
| dc.subject | Seronegative autoimmune hepatitis WHO | |
| dc.subject | Child, Preschool | |
| dc.subject | HSCT | |
| dc.subject | hematopoietic stem cell transplantation | |
| dc.subject | pediatric seronegative autoimmune hepatitis | |
| dc.subject | Female | |
| dc.subject | hemoglobin HSCT | |
| dc.subject | partial remission SARS-CoV-2 | |
| dc.subject | CR | |
| dc.subject | Immunosuppressive Agents | |
| dc.subject | MRI | |
| dc.subject | severe acute respiratory syndrome coronavirus 2 | |
| dc.subject | Ig | |
| dc.subject | aplastic anemia | |
| dc.subject | Adolescent | |
| dc.subject | complete remission | |
| dc.subject | alanine aminotransferase | |
| dc.subject | Immunology | |
| dc.subject | aspartate aminotransferase ATG | |
| dc.subject | partial remission | |
| dc.subject | SAIH | |
| dc.subject | liver transplantation LTd | |
| dc.subject | EBV | |
| dc.subject | bone marrow aspiration/biopsy CMV | |
| dc.subject | LTd | |
| dc.subject | gamma-glutamyl transpeptidase Hb | |
| dc.subject | Epstein-Barr virus | |
| dc.subject | Humans | |
| dc.subject | cytomegalovirus CR | |
| dc.subject | complete remission EBV | |
| dc.subject | FV | |
| dc.subject | AST | |
| dc.subject | cytomegalovirus | |
| dc.subject | Retrospective Studies | |
| dc.subject | liver transplanted patients | |
| dc.subject | SARS-CoV-2 | |
| dc.subject | Hb | |
| dc.subject | Antithymocyte Globulin BMA/B | |
| dc.subject | prothrombin time PR | |
| dc.subject | dysimmunity | |
| dc.subject | polymerase chain reaction PT | |
| dc.subject | COVID-19 | |
| dc.subject | Infant | |
| dc.subject | acute liver failure | |
| dc.subject | hemoglobin | |
| dc.subject | liver transplanted patients MRI | |
| dc.subject | RC581-607 | |
| dc.subject | AA | |
| dc.subject | prothrombin time | |
| dc.subject | GGT | |
| dc.subject | immunoglobulin LT | |
| dc.subject | ATG | |
| dc.subject | Antithymocyte Globulin | |
| dc.subject | ALF | |
| dc.subject | World Health Organization pediatric seronegative autoimmune hepatitis | |
| dc.subject | aplastic anemia ALT | |
| dc.subject | Immunologic diseases. Allergy | |
| dc.subject | immunoglobulin | |
| dc.title | Increased incidence of seronegative autoimmune hepatitis in children during SARS-CoV-2 pandemia period | |
| dc.type | publication |